Literature DB >> 23543060

MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation.

Xiaobin Luo1, Zhenwei Pan, Hongli Shan, Jiening Xiao, Xuelin Sun, Ning Wang, Huixian Lin, Ling Xiao, Ange Maguy, Xiao-Yan Qi, Yue Li, Xu Gao, Deli Dong, Yong Zhang, Yunlong Bai, Jing Ai, Lihua Sun, Hang Lu, Xiao-Yan Luo, Zhiguo Wang, Yanjie Lu, Baofeng Yang, Stanley Nattel.   

Abstract

Atrial fibrillation (AF) is a highly prevalent arrhythmia with pronounced morbidity and mortality. Inward-rectifier K+ current (IK1) is believed to be an important regulator of reentrant-spiral dynamics and a major component of AF-related electrical remodeling. MicroRNA-26 (miR-26) is predicted to target the gene encoding KIR2.1, KCNJ2. We found that miR-26 was downregulated in atrial samples from AF animals and patients and this downregulation was accompanied by upregulation of IK1/KIR2.1 protein. miR-26 overexpression suppressed expression of KCNJ2/KIR2.1. In contrast, miR-26 knockdown, inhibition, or binding-site mutation enhanced KCNJ2/KIR2.1 expression, establishing KCNJ2 as a miR-26 target. Knockdown of endogenous miR-26 promoted AF in mice, whereas adenovirus-mediated expression of miR-26 reduced AF vulnerability. Kcnj2-specific miR-masks eliminated miR-26-mediated reductions in Kcnj2, abolishing miR-26's protective effects, while coinjection of a Kcnj2-specific miR-mimic prevented miR-26 knockdown-associated AF in mice. Nuclear factor of activated T cells (NFAT), a known actor in AF-associated remodeling, was found to negatively regulate miR-26 transcription. Our results demonstrate that miR-26 controls the expression of KCNJ2 and suggest that this downregulation may promote AF.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543060      PMCID: PMC3635715          DOI: 10.1172/JCI62185

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress.

Authors:  Jiening Xiao; Huixian Lin; Xiaobin Luo; Xiaoyan Luo; Zhiguo Wang
Journal:  EMBO J       Date:  2011-01-07       Impact factor: 11.598

2.  MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation.

Authors:  Yanjie Lu; Ying Zhang; Ning Wang; Zhenwei Pan; Xu Gao; Fengmin Zhang; Yong Zhang; Hongli Shan; Xiaobin Luo; Yunlong Bai; Lihua Sun; Wuqi Song; Chaoqian Xu; Zhiguo Wang; Baofeng Yang
Journal:  Circulation       Date:  2010-11-22       Impact factor: 29.690

Review 3.  Recent advances in the molecular pathophysiology of atrial fibrillation.

Authors:  Reza Wakili; Niels Voigt; Stefan Kääb; Dobromir Dobrev; Stanley Nattel
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

4.  Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets.

Authors:  Sami F Noujaim; Jeanne A Stuckey; Daniela Ponce-Balbuena; Tania Ferrer-Villada; Angelica López-Izquierdo; Sandeep Pandit; Conrado J Calvo; Krzysztof R Grzeda; Omer Berenfeld; José A Sánchez Chapula; José Jalife
Journal:  FASEB J       Date:  2010-06-28       Impact factor: 5.191

5.  Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation.

Authors:  Masahide Harada; Xiaobin Luo; Xiao Yan Qi; Artavazd Tadevosyan; Ange Maguy; Balazs Ordog; Jonathan Ledoux; Takeshi Kato; Patrice Naud; Niels Voigt; Yanfen Shi; Kaichiro Kamiya; Toyoaki Murohara; Itsuo Kodama; Jean-Claude Tardif; Ulrich Schotten; David R Van Wagoner; Dobromir Dobrev; Stanley Nattel
Journal:  Circulation       Date:  2012-09-19       Impact factor: 29.690

Review 6.  Novel molecular targets for atrial fibrillation therapy.

Authors:  Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

7.  Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves.

Authors:  Vishal Nigam; Hans H Sievers; Brian C Jensen; Holger A Sier; Paul C Simpson; Deepak Srivastava; Salah A Mohamed
Journal:  J Heart Valve Dis       Date:  2010-07

8.  The principles of MiRNA-masking antisense oligonucleotides technology.

Authors:  Zhiguo Wang
Journal:  Methods Mol Biol       Date:  2011

9.  miR133a regulates cardiomyocyte hypertrophy in diabetes.

Authors:  Biao Feng; Shali Chen; Biju George; Qingping Feng; Subrata Chakrabarti
Journal:  Diabetes Metab Res Rev       Date:  2010-01       Impact factor: 4.876

10.  Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

Authors:  Robert E Lanford; Elisabeth S Hildebrandt-Eriksen; Andreas Petri; Robert Persson; Morten Lindow; Martin E Munk; Sakari Kauppinen; Henrik Ørum
Journal:  Science       Date:  2009-12-03       Impact factor: 47.728

View more
  101 in total

Review 1.  Advances in exploring the role of microRNAs in the pathogenesis, diagnosis and therapy of cardiac diseases in China.

Authors:  Z W Pan; Y J Lu; B F Yang
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

Review 2.  Cardiac ion channels.

Authors:  Birgit T Priest; Jeff S McDermott
Journal:  Channels (Austin)       Date:  2015-08-20       Impact factor: 2.581

Review 3.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

4.  Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model.

Authors:  Na Li; David Y Chiang; Sufen Wang; Qiongling Wang; Liang Sun; Niels Voigt; Jonathan L Respress; Sameer Ather; Darlene G Skapura; Valerie K Jordan; Frank T Horrigan; Wilhelm Schmitz; Frank U Müller; Miguel Valderrabano; Stanley Nattel; Dobromir Dobrev; Xander H T Wehrens
Journal:  Circulation       Date:  2014-01-07       Impact factor: 29.690

5.  MicroRNA-mediated downregulation of K+ channels in pulmonary arterial hypertension.

Authors:  Aleksandra Babicheva; Ramon J Ayon; Tengteng Zhao; Jose F Ek Vitorin; Nicole M Pohl; Aya Yamamura; Hisao Yamamura; Brooke A Quinton; Manqing Ba; Linda Wu; Keeley S Ravellette; Shamin Rahimi; Francesca Balistrieri; Angela Harrington; Rebecca R Vanderpool; Patricia A Thistlethwaite; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-25       Impact factor: 5.464

Review 6.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 7.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

Review 8.  MicroRNAs in cardiovascular ageing.

Authors:  Timon Seeger; Reinier A Boon
Journal:  J Physiol       Date:  2015-07-05       Impact factor: 5.182

Review 9.  Serine/Threonine Phosphatases in Atrial Fibrillation.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Xander H T Wehrens; Dobromir Dobrev
Journal:  J Mol Cell Cardiol       Date:  2017-01-07       Impact factor: 5.000

10.  Short- and long-term inhibition of cardiac inward-rectifier potassium channel current by an antiarrhythmic drug bepridil.

Authors:  Fangfang Ma; Hiroki Takanari; Kimiko Masuda; Masaki Morishima; Katsushige Ono
Journal:  Heart Vessels       Date:  2015-10-26       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.